NZ540515A - Pyrazole derivatives useful as COX-I inhibitors - Google Patents

Pyrazole derivatives useful as COX-I inhibitors

Info

Publication number
NZ540515A
NZ540515A NZ540515A NZ54051503A NZ540515A NZ 540515 A NZ540515 A NZ 540515A NZ 540515 A NZ540515 A NZ 540515A NZ 54051503 A NZ54051503 A NZ 54051503A NZ 540515 A NZ540515 A NZ 540515A
Authority
NZ
New Zealand
Prior art keywords
compound
pyrazol
mixture
pct
esi
Prior art date
Application number
NZ540515A
Other languages
English (en)
Inventor
Fumiyuki Shirai
Hidenori Azami
Natsuko Kayakiri
Kazuo Okumura
Katsuya Nakamura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002953019A external-priority patent/AU2002953019A0/en
Priority claimed from AU2002953602A external-priority patent/AU2002953602A0/en
Priority claimed from AU2003902015A external-priority patent/AU2003902015A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NZ540515A publication Critical patent/NZ540515A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ540515A 2002-12-02 2003-11-14 Pyrazole derivatives useful as COX-I inhibitors NZ540515A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2002953019A AU2002953019A0 (en) 2002-12-02 2002-12-02 Azole derivatives
AU2002953602A AU2002953602A0 (en) 2002-12-30 2002-12-30 New compounds
AU2003902015A AU2003902015A0 (en) 2003-04-29 2003-04-29 Azole derivatives
PCT/JP2003/014489 WO2004050632A1 (en) 2002-12-02 2003-11-14 Pyrazole derivatives useful as cox-i inhibitors

Publications (1)

Publication Number Publication Date
NZ540515A true NZ540515A (en) 2008-01-31

Family

ID=32474716

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ540515A NZ540515A (en) 2002-12-02 2003-11-14 Pyrazole derivatives useful as COX-I inhibitors

Country Status (15)

Country Link
US (2) US7183306B2 (https=)
EP (1) EP1567503B1 (https=)
JP (1) JP4419078B2 (https=)
KR (1) KR20050083761A (https=)
AR (1) AR042273A1 (https=)
AT (1) ATE538097T1 (https=)
BR (1) BR0316332A (https=)
CA (1) CA2505945A1 (https=)
ES (1) ES2379076T3 (https=)
MX (1) MXPA05005742A (https=)
NO (1) NO20053215L (https=)
NZ (1) NZ540515A (https=)
PL (1) PL377778A1 (https=)
TW (1) TW200410942A (https=)
WO (1) WO2004050632A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055502A1 (en) * 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
KR20050083761A (ko) 2002-12-02 2005-08-26 후지사와 야꾸힝 고교 가부시키가이샤 Ｃｏｘ－ｉ저해제로서 유용한 피라졸 유도체
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
ATE440085T1 (de) * 2004-02-20 2009-09-15 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
US20080064682A1 (en) * 2004-07-01 2008-03-13 Daiichi Pharmaceutical Co., Ltd. Pyrazole Derivatives
WO2006013962A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 抗血小板薬およびその製造方法
EP2368881A1 (en) * 2005-01-10 2011-09-28 University of Connecticut Heteropyrazole analogs acting on cannabinoid receptors
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0516661D0 (en) * 2005-08-13 2005-09-21 Astrazeneca Ab Therapeutic agents
JPWO2007111323A1 (ja) 2006-03-27 2009-08-13 東レ株式会社 ウレイド誘導体およびその医薬用途
EP2070908A4 (en) 2006-09-07 2011-08-10 Univ Okayama Nat Univ Corp COMPOUND WITH BENZAMIDE KELET AND CYCLOOXYGENASE (COX-1) -ELECTIVE HEMORATIVE EFFECT
EP2121659B1 (en) * 2006-12-18 2013-05-15 7TM Pharma A/S Modulators of cb1 receptors
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
WO2008114859A1 (ja) * 2007-03-22 2008-09-25 Astellas Pharma Inc. ピラゾール誘導体を含有する医薬組成物
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
JP5704925B2 (ja) 2008-02-08 2015-04-22 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−カンナビノイドコンジュゲート
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
EP2356100A1 (en) * 2008-10-02 2011-08-17 Cambrex Karlskoga AB New process for preparing diketones and medicaments
TWI435874B (zh) 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
DE102011055815A1 (de) * 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
MX2019001813A (es) 2016-08-15 2019-05-20 Bayer Cropscience Ag Procedimiento para la preparacion de pyrazoles de 3-amino-1-(2,6-disustituido-fenilo).
JP7071981B2 (ja) * 2016-09-07 2022-05-19 エフジーエイチ バイオテック，インコーポレーテッド 疾患の治療のための二置換ピラゾール化合物
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN115611790A (zh) * 2022-10-31 2023-01-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种甲硫基甲基苯基醚的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164381A (en) 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US4826868A (en) 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5051518A (en) 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5550147A (en) 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
WO1996014302A1 (en) 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
ES2136018B1 (es) 1997-06-17 2000-07-01 Menarini Lab Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos.
CA2332957A1 (en) 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
WO2000018741A2 (en) * 1998-09-30 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds as cox-2 inhibitors
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
DE60006057T2 (de) * 1999-12-03 2004-05-27 Pfizer Products Inc., Groton Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
AU2001255600A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
WO2002055502A1 (en) 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
EP1492773B1 (en) 2002-04-05 2009-02-04 Cadila Healthcare Ltd. 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
KR20050083761A (ko) 2002-12-02 2005-08-26 후지사와 야꾸힝 고교 가부시키가이샤 Ｃｏｘ－ｉ저해제로서 유용한 피라졸 유도체
CN100421632C (zh) 2005-02-01 2008-10-01 金磊 人工心脏瓣膜成形环

Also Published As

Publication number Publication date
BR0316332A (pt) 2005-09-27
JP2006514095A (ja) 2006-04-27
JP4419078B2 (ja) 2010-02-24
WO2004050632A1 (en) 2004-06-17
TW200410942A (en) 2004-07-01
EP1567503B1 (en) 2011-12-21
MXPA05005742A (es) 2005-08-16
ES2379076T3 (es) 2012-04-20
ATE538097T1 (de) 2012-01-15
KR20050083761A (ko) 2005-08-26
AR042273A1 (es) 2005-06-15
HK1087102A1 (zh) 2006-10-06
US20070112037A1 (en) 2007-05-17
PL377778A1 (pl) 2006-02-20
US20040116475A1 (en) 2004-06-17
NO20053215D0 (no) 2005-06-30
NO20053215L (no) 2005-09-01
EP1567503A1 (en) 2005-08-31
CA2505945A1 (en) 2004-06-17
US7183306B2 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
NZ540515A (en) Pyrazole derivatives useful as COX-I inhibitors
US6750230B2 (en) Pyrazole derivatives
KR100569324B1 (ko) Ｈｉｖ 치료용 피라졸 유도체
CN100486573C (zh) 硝基化的和亚硝基化的环加氧酶-2抑制剂、组合物及其用途
CN101595102B (zh) 二芳基醚脲化合物
WO2007052843A1 (ja) 複素環アミド化合物およびその用途
KR100511884B1 (ko) 트리아졸 유도체
WO2004060367A1 (en) Imidazole and triazole derivatives useful as selective cox-1 inhibitors
WO2004089937A1 (ja) ７員複素環誘導体
WO2021107125A1 (ja) リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途
US7220772B2 (en) Pyrazole derivatives
CN100482647C (zh) 用作cox-1抑制剂的吡唑衍生物
AU2003302635A1 (en) Pyrazole derivatives useful as cox-i inhibitors
HK1087102B (en) Pyrazole derivatives useful as cox-i inhibitors
MXPA05003641A (es) Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el virus de la inmunodeficiencia humana.
HK1063781B (en) Pyrazole derivatives for treating hiv
HK1139652B (en) Biaryl ether urea compounds

Legal Events

Date Code Title Description
PSEA Patent sealed